STING Agonism Reprograms Tumor-Associated Macrophages and Overcomes Resistance to PARP Inhibition in BRCA1-Deficient Models of Breast Cancer

Using a syngeneic genetically-engineered mouse model of breast tumor driven by Brca1 deficiency, researchers showed that tumor-associated macrophages blunted PARP inhibitors efficacy both in vivo and in vitro.